Key Product Details

Species Reactivity

Cytomegalovirus, Virus

Applications

ELISA, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Frozen

Label

FITC (Excitation = 495 nm, Emission = 519 nm)

Antibody Source

Monoclonal Mouse IgG2A Clone # hCMV34

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all Cytomegalovirus gB Antibodies »

Product Specifications

Immunogen

Native cytomeglaovirus extracts from infected human cells.

Reactivity Notes

0

Specificity

Recognizes cytomegalovirus glycoprotein B, a viral ligand for CD209 which allows capture of viral particles by dendritic cells. This does not react with HSV, VSV or EBV.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2A

Applications for Cytomegalovirus gB Antibody (hCMV34) [FITC]

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Immunocytochemistry/ Immunofluorescence

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry-Frozen

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: Cytomegalovirus gB

Human cytomegalovirus, also called HCMV or human herpesvirus 5, is a double-stranded DNA, enveloped virus of 230-250 kilobases (kb) that is a member of the Herpesviridae family and the subfamily Betaherpesvirinae (1,2). Other herpesviruses, which share the characteristic of lifelong latency following primary infection, include herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), varicella zoster virus (VSV), and Epstein-Barr virus (EBV) (1). Cytomegalovirus entry into cells is mediated by a trimeric complex of glycoproteins gH, gL, and gO and a pentamer made of proteins gH, gL, UL128, UL130, and UL131A (1,3). The trimer binds PDGFRalpha for entry into fibroblasts while the pentamer binds neuropilin-2 for entry into endothelial and epithelial cells (1,4). Additionally, the fusion protein glycoprotein B (gB) plays a pivotal role for cytomegalovirus entry into the host cell membrane (1,3).

Cytomegalovirus is a common virus, infecting ~60% of adults in developed countries and over 90% in developing countries, as indicated by presence of specific IgG antibodies (2-4). Although a majority of people infected remain asymptomatic, immunocompromised people, organ transplant recipients, and fetuses and newborns are more susceptible to HCMV-associated diseases (1-4). Annually, up to 2% of newborns are born with HCMV, making it the most common congenital infection (2-4). Cytomegalovirus is known to cause sensorineural hearing loss (SNHL), mental retardation, chorioretinitis, skin lesions, as well as end organ disease (3,5). There are a few CMV therapeutics approved by FDA including valganciclovir and letermovir; however, despite some benefits, there is the need for new antivirals and combination therapies (5). Potential new treatment options include monoclonal antibodies and sirtuins (5).

References

1. Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol. 2021;19(2):110-121. https://doi.org/10.1038/s41579-020-00448-w

2. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-773. https://doi.org/10.1038/s41579-021-00582-z

3. Krstanovic F, Britt WJ, Jonjic S, Brizic I. Cytomegalovirus Infection and Inflammation in Developing Brain. Viruses. 2021;13(6):1078. Published 2021 Jun 4. https://doi.org/10.3390/v13061078

4. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288-297. https://doi.org/10.1002/path.4437

5. Acosta E, Bowlin T, Brooks J, et al. Advances in the Development of Therapeutics for Cytomegalovirus Infections. J Infect Dis. 2020;221(Suppl 1):S32-S44. https://doi.org/10.1093/infdis/jiz493

Alternate Names

CMV, CMV glycoprotein B, CMV glycoprotein GP55, Cytomegalovirus glycoprotein GP55, gB, Glycoprotein B, Glycoprotein GP55, HCMV, HCMV glycoprotein B, HCMV glycoprotein GP55, HHV 5 glycoprotein B, HHV 5 glycoprotein GP55, HHV5 glycoprotein B, HHV5 glycoprotein GP55, Human herpesvirus 5 glycoprotein B, Human herpesvirus 5 glycoprotein GP55, UL55

Additional Cytomegalovirus gB Products

Product Documents for Cytomegalovirus gB Antibody (hCMV34) [FITC]

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for Cytomegalovirus gB Antibody (hCMV34) [FITC]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.